Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2022-09-01 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total funds used, and compliance with regulatory guidelines. It references previous announcements about the share buyback plan and updates on the repurchase progress. The document length is short (1274 characters) and it is clearly an update on the company's share repurchase activity, not a full financial report or earnings release. Therefore, it fits the category of 'Transaction in Own Shares' (POS).
2022-09-01 Chinese
金宇生物技术股份有限公司关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) for investors. It includes the meeting time, location, participation method, and contact information. It references the company's 2022 half-year report but does not contain the report itself or substantive financial data. The document is short (1582 characters) and serves to inform investors about the upcoming event rather than presenting financial results or analysis. Therefore, it is classified as an Investor Presentation (IP) type, as it relates to a detailed presentation for investors focusing on financials and company performance, specifically an earnings explanation meeting.
2022-08-29 Chinese
金宇生物技术股份有限公司关于董事长代行董事会秘书职责的公告
Board/Management Information Classification · 95% confidence The document is a short announcement regarding the chairman acting as the board secretary due to a vacancy exceeding three months. It references regulatory requirements and previous announcements but does not contain financial data, audit information, or detailed reports. It is an announcement about board/management role changes rather than a full management report or regulatory filing. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management role changes, not a report or certification.
2022-08-29 Chinese
金宇生物技术股份有限公司2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive details. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 2559 characters, which is relatively short but contains actual financial data, not just an announcement or a link to a report. Therefore, it should be classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
金宇生物技术股份有限公司2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度报告" which translates to "2022 Half-Year Report". It contains detailed financial data, management discussion and analysis, company information, business overview, and operational details for the period January 1, 2022 to June 30, 2022. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
金宇生物技术股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the prices, total amounts paid, and compliance with regulatory guidelines. It references previous announcements about the share buyback plan and updates on the repurchase progress. The document length is short (1338 characters) and it is clearly an update on the share repurchase activity, not a full financial report or an announcement of a report publication. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2022-08-02 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.